Madrigal Pharmaceuticals, Inc. (MDGL)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Madrigal Pharmaceuticals, Inc. (MDGL)
Go deeper and ask any question about MDGL
Company Performance
Current Price
as of Sep 18, 2024$233.16
P/E Ratio
N/A
Market Cap
$5.06B
Description
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.
Metrics
Overview
- HQWest Conshohocken, PA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerMDGL
- Price$233.16-0.09%
Trading Information
- Market Cap$5.06B
- Float83.17%
- Average Daily Volume (1m)195,779
- Average Daily Volume (3m)281,541
- EPS-$25.50
Company
- Revenue$14.64M
- Rev Growth (1yr)N/A
- Net Income-$151.97M
- Gross Margin93.83%
- EBITDA Margin-1,108.55%
- EBITDA-$162.27M
- EV$5.05B
- EV/Revenue345.09
- P/EN/A
- P/S340.91
Documents
SEC Filings
Factset Street Account